11 completed, 4 active not recruiting, 1 not yet recruiting, 1 recruiting. 7 Phase 1, 5 Not applicable, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Active not recruiting 1 |
| Not applicable | 5 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 3, Active not recruiting 2 |
Follow Thyroid Gland Medullary Carcinoma: new trials by email Literature Review of Thyroid Gland Medullary Carcinoma trials Research Report on Thyroid Gland Medullary Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma | Not applicable | Not yet recruiting | Jonsson Comprehensive Cancer Center | 100 | 2027-09-02 | 2026-10-19 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-05-20 |
| Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers Decision Aid, Questionnaire Administration - Thyroid Gland Medullary Carcinoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 120 | 2019-04-09 | 2026-07-16 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
| Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer Computed Tomography, Dual X-ray Absorptiometry, Physical Examination - Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma | Not applicable | Completed | M.D. Anderson Cancer Center | 23 | 2015-11-16 | 2024-03-05 |
| Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer radionuclide imaging, positron emission tomography, laboratory biomarker analysis - Breast Cancer, Colon Cancer | Not applicable | Active not recruiting | City of Hope Medical Center | 20 | 2015-11-11 | 2026-09-24 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2012-11-14 | 2023-12-22 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-10-01 | 2016-07-15 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma | Phase 1 | Completed | University of Southern California | 19 | 2010-06-01 | 2016-06-13 |
| Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer sunitinib malate - Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer | Phase 2 | Completed | University of Washington | 35 | 2007-07-01 | 2017-04-25 |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer vorinostat - Insular Thyroid Cancer, Recurrent Thyroid Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2005-12-01 | 2014-08-11 |
| Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer tanespimycin - Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2004-12-01 | 2017-02-15 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma | Phase 1 | Completed | Mayo Clinic | 96 | 2004-12-01 | 2024-08-21 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer gefitinib - Anaplastic Thyroid Cancer, Insular Thyroid Cancer | Not applicable | Completed | National Cancer Institute (NCI) | 40 | 2003-08-01 | 2013-01-14 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant - Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder | Phase 1 | Completed | National Cancer Institute (NCI) | 48 | 2001-11-01 | 2013-01-25 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 1999-08-01 | 2013-02-28 |
Carcinoma, Medullary (17) · Thyroid Neoplasms (8) · Thyroid Cancer, Papillary (6) · Adenocarcinoma, Follicular (5) · Breast Neoplasms (5) · Carcinoma, Hepatocellular (5) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Renal Cell (4) · Pancreatic Neoplasms (4) · Salivary Gland Neoplasms (4) · Breast Neoplasms, Male (3) · Carcinoma, Islet Cell (3) · Carcinoma, Merkel Cell (3) · Colonic Neoplasms (3) · Gallbladder Neoplasms (3)
Adenocarcinoma (17) · Carcinoma (17) · Carcinoma, Neuroendocrine (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Neoplasms, Ductal, Lobular, and Medullary (17) · Neoplasms, Germ Cell and Embryonal (17) · Neoplasms, Glandular and Epithelial (17) · Neoplasms, Nerve Tissue (17) · Neuroectodermal Tumors (17) · Neuroendocrine Tumors (16) · Endocrine Gland Neoplasms (14) · Endocrine System Diseases (14) · Neoplasms by Site (14) · Head and Neck Neoplasms (9)
cabozantinib (3) · Everolimus (2) · High-Energy Shock Waves (2) · Magnetic Resonance Spectroscopy (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Absorptiometry, Photon (1) · Acetates (1) · Decision Support Techniques (1) · FAPI-46 (1) · Fluorodeoxyglucose F18 (1) · Gefitinib (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1) · Neck Dissection (1)
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (3) · Jonsson Comprehensive Cancer Center (2) · City of Hope Medical Center (1) · Mayo Clinic (1) · University of Southern California (1) · University of Washington (1)
United States (17) · Canada (1)
Agustin Garcia (1) · Elizabeth G Grubbs, MD (1) · James Wu, MD (1) · James Yao (1) · Jeffrey Moley (1) · Jeffrey Wong (1) · Jeremie Calais (1) · Julian R. Molina, M.D., Ph.D. (1) · Manisha Shah (1) · Margaret von Mehren (1) · Mark Zafereo (1) · Meredith K Chuk (1) · Naifa L Busaidy (1) · Renato Martins (1) · Shirish Gadgeel (1)
PMID 18854394, PMID 25900182, PMID 31401903, PMID 36154291
N01CM62207 (2), N01CM62205 (1), P30CA015083 (1), P30CA016672 (1), U01CA062461 (1), U01CA076576 (1), U10CA032102 (1), U10CA180886 (1), UM1CA097452 (1)